Findings from the Keynote-826 study indicate favourable outcomes on the use of pembrolizumab and chemotherapy with or without bevacizumab as a standard treatment regimen for patients with persistent, recurrent, or metastatic cervical cancer. Cervical cancer "is commonly associate with bleeding, fatigue, pain, bladder, and bowel dysfunction, leg swelling, and sexual dysfunction", symptoms which worsen in advanced or recurrent stages. The goal of the standard treatment regimen mentioned above is to prolong, preserve, and improve health-related quality of life.
To learn more about this study, click here.
Source mentioned:
Monk BJ, Tewari KS, Dubot C, et al. Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology; Published online 3 March 2023. DOI: https://doi.org/10.1016/S1470-2045(23)00052-9
No comments:
Post a Comment